MarginsXMarginsX
Home › Markets › Health Care › YDES

YD Bio Limited (YDES)

YDES trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.83
-1.02% on the day
Market cap
$342.1M
Small cap
Revenue · 2025
$597K
+16.9% on 2024
Net income · 2025
-$8.3M
-1392.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2011674/000121390026050282/0001213900-26-050282-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerYDES on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0002011674
SEC industry codeServices-Medical Laboratories
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$597K
Net income-$8.3M
Operating income-$5.3M
Net margin-1392.6%
Operating margin-883.3%
Revenue growth+16.9%
Cash$6.0M
Total assets$13.8M
P/E (computed)Net income was not positive
P/S (computed)573.2×

Warning signs

Cash runway
10.9 months
$6.0M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
Yes
20-F filed April 30, 2026
Insider net buying, 12 months
$129K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions and Company's recurring losses from operations raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the date of this report. 71 We may need to raise additional funds to finance our operations through further equity or equity-linked offerings or debt financing arrangements."
20-F 2026-04-30
Cash and burn$6.0M cash; operating cash flow -$1.6M a quarter.Report 2025-12-31
Shares outstanding70,789,261 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMaloneBailey, LLP, Houston, Texas, United StatesPCAOB Form AP 2026-05-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $129K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$597K-$8.3M-$6.6M$6.0M$7K$597K20-F 2026-04-30
FY 2024
2024-12-31
$510K-$1.4M-$1.2M$3.1MNo debt tags$510K20-F 2026-04-30
FY 2023
2023-12-31
$350K$14K-$56K$87KNo debt tags$350K20-F 2026-04-30

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS SUPPLEMENT
424B32026-09-01
Latest annual report
ANNUAL REPORT
20-F2026-04-30
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-09-01

Source: SEC EDGAR submissions feed, 80 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-18.3%
1 month-20.0%
3 months+94.4%
Year to date-60.0%
1 year-51.8%
From 52-week high-68.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
YDESWYD Bio Limited Warrants$0.4870

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
FLGTFulgent Genetics Inc.$24.07-2.37%$672.6M
TLSITriSalus Life Sciences Inc.$2.27-6.58%$140.1M
BNRBurning Rock Biotech Limited$12.74-4.43%$134.4M
CSTLCastle Biosciences Inc.$32.75-3.08%$1.0B
FRNMFreenome Inc.$10.09-3.07%$1.1B
KEQUKewaunee Scientific Corporation$35.05-1.81%$101.5M
BDSXBiodesix Inc.$9.00-8.91%$99.8M
XGNExagen Inc.$3.77-8.72%$96.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier